Abir received her doctorate in December 2019 at Lille University in France and came to the United States to work as a postdoctoral researcher in the group of Dr. Giuseppe Carlucci. She has a strong interest in drug delivery and nanomedicine. Her expertise covers a broad field of nanomedicine research from biochemistry over various in vitro techniques to radiolabeling and in vivo studies. She currently focuses on investigating the development and functionalization of nanoparticles as a selective target to deploy a nuclear drug that will specifically ablate cancer cells, which aims at establishing fibroblast activation protein-targeted nanotheranostics as a viable treatment modality for cancer. Knowledge gained from these studies will aid the clinical translation of protein-targeted nanotheranostics as a new treatment modality in nanomedicine.

Associated Faculty

Giuseppe Carlucci, Ph.D.Lab website